Biography for Mark Hollmer
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.
Articles by Mark Hollmer
France's Stentys is celebrating more positive clinical data stemming from the use of its self-apposing stent to treat acute heart attacks.
Medtronic scored a pivotal CE mark that will help expand the market for its CoreValve transcatheter aortic valve replacement (TAVR). This latest regulatory nod grants surgeons the ability to use the tech for transcathether valve-in-valve procedures where the new part is placed inside an old, expired replacement valve.
Eli Lilly will work with Corgenix Medical to develop companion diagnostics for its cancer drug pipeline.
Pee on a stick, and then learn whether you have prostate cancer. That's the gist of a new, inexpensive test UC Irvine researchers have developed that would use urine instead of blood to screen for prostate cancer.
Covidien is celebrating results from a trial showing one of its ablation therapy devices helped prevent an advance to esophageal cancer by eliminating a precancerous condition known as Barrett's esophagus.
A Los Angeles Times columnist is sounding off against efforts to repeal the 2.3% medical device industry tax, calling manufacturers' ongoing lobbying campaign to undo the measure a "narrow-minded and dishonest" campaign.
Given Imaging CEO Homi Shamir predicts an FDA regulatory sign-off for the company's new endoscopic pill camera by the start of the 2013 fourth quarter, made possible, in part, by promising new data from several European studies.
Doctors may be able to predict the likelihood of postpartum depression, Johns Hopkins researchers believe, by using a blood test that screens for two mutated genes. They studied mice and 52 pregnant women to identify the epigenetic biomarkers in question.
In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
OrbusNeich Medical called the cops on Boston Scientific in Germany in a nasty escalation of their ongoing stent patent dispute.